Epigenetic Alteration by DNA Methylation of ESR1, MYOD1 and hTERT Gene Promoters is Useful for Prediction of Response in Patients of Locally Advanced Invasive Cervical Carcinoma Treated by Chemoradiation.

Clinical Oncology : a Journal of the Royal College of Radiologists
S SoodR Srinivasan

Abstract

Locally advanced invasive cervical cancer [International Federation of Gynecology and Obstetrics (FIGO) IIB/III] is treated by chemoradiation. The response to treatment is variable within a given FIGO stage. Therefore, the aim of the present study was to evaluate the gene promoter methylation profile and corresponding transcript expression of a panel of six genes to identify genes which could predict the response of patients treated by chemoradiation. In total, 100 patients with invasive cervical cancer in FIGO stage IIB/III who underwent chemoradiation treatment were evaluated. Ten patients developed systemic metastases during therapy and were excluded. On the basis of patient follow-up, 69 patients were chemoradiation-sensitive, whereas 21 were chemoradiation-resistant. Gene promoter methylation and gene expression was determined by TaqMan assay and quantitative real-time PCR, respectively, in tissue samples. The methylation frequency of ESR1, BRCA1, RASSF1A, MLH1, MYOD1 and hTERT genes ranged from 40 to 70%. Univariate and hierarchical cluster analysis revealed that gene promoter methylation of MYOD1, ESR1 and hTERT could predict for chemoradiation response. A pattern of unmethylated MYOD1, unmethylated ESR1 and methylated h...Continue Reading

References

Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Mar 27, 2001·International Journal of Cancer. Journal International Du Cancer·G B WismanA G van der Zee
Apr 4, 2003·International Journal of Cancer. Journal International Du Cancer·Mei Y YuKai F To
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andreas WidschwendterMartin Widschwendter
May 6, 2004·Cancer Research·Gopeshwar NarayanVundavalli V V S Murty
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andreas WidschwendterMartin Widschwendter
Jul 15, 2004·Annals of the New York Academy of Sciences·Hannes M MüllerMartin Widschwendter
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Partha M Das, Rakesh Singal
Jul 1, 2006·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Amit Kumar AdhyaFiruza D Patel
Dec 7, 2007·Nature Reviews. Genetics·Steven Henikoff
Jun 29, 2010·The American Journal of Pathology·Yali ZhaiKathleen R Cho
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Oct 4, 2012·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Ericka WiebeGillian Thomas
Oct 25, 2013·International Journal of Molecular Sciences·Sibaji SarkarMcKenna Longacre
Nov 29, 2013·Cancer Cell International·Bin ZhangJunye Liu
Jan 3, 2015·Nature Reviews. Genetics·Daniel Holoch, Danesh Moazed

❮ Previous
Next ❯

Citations

Jun 1, 2018·International Journal of Genomics·Chunyang FengTianmin Xu
Apr 14, 2017·BMC Cancer·Marjolaine NgolloDominique Bernard-Gallon
Dec 30, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sophia MastorakiEvi Lianidou
Jan 25, 2021·Pathology, Research and Practice·Sara RavaioliSara Bravaccini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.